Compare Adaptive Biotechnologies Corp (ADPT) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Endeavour Silver Corp — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Endeavour Silver Corp trades at $7.63 (market cap $2.37B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | EXK | |
|---|---|---|
Market Cap | $3.33B | $2.37B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $14.12 |
52-Week Low | $10.24 | $4.84 |
Enterprise Value | $3.19B | $2.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Endeavour Silver (EXK) trades at $8.51, down 0.58% on the day, with a neutral technical signal and bearish moving averages. The company reported strong Q1 2026 results with earnings of $0.21 per share beating expectations, driven by record production. However, full-year 2025 showed a net loss of $119.10 million despite revenue growth. Recent news highlights high-grade mineralization discoveries at its Terronera mine, supporting future production potential.
The outlook is mixed: analyst consensus is strongly bullish (78.57% buy ratings), but profitability remains a concern with negative margins. Key risks include execution on growth projects and silver price volatility. Upside catalysts hinge on sustained operational improvements and favorable commodity markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
